BLRX Overview
Upcoming Projects (BLRX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BLRX)
-
Delving into BiolineRx's APHEXDA (Motixafortide)(BL-8040): Stem Cell Mobilization in Multiple Myeloma with a PDUFA Date of September 9, 2023
Ticker: BLRX
Executed On: Sep 07, 2023 at 02:00 PM EDT
Expired Projects (BLRX)
Upcoming & Overdue Catalysts (BLRX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BLRX)
-
Top-line results for BL-8040 in Mobilization and collection of bone marrow stem cells expected by the end of 2017
Ticker: BLRX
Occurred on: Nov 02, 2017 -
BL-8040 in Mobilization and collection of bone marrow stem cells Phase 2 Partial data due 1Q 2017
Ticker: BLRX
Occurred on: Mar 20, 2017 -
BioLineRX (BLRX) Initiates Phase 2a Trial Evaluating BL-8040 + Merck's (MRK) KEYTRUDA in Treatment of Pancreatic Cancer
Tickers: BLRX, MRK
Occurred on: Sep 20, 2016
Strategic Initiatives (BLRX)
-
BioLineRx (BLRX) In-Licenses Novel Anti-Inflammatory Candidate for Dry Eye Syndrome (DES) from Hebrew University of Jerusalem
Ticker: BLRX
Announcement Date: Nov 21, 2016 -
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Ticker: BLRX
Announcement Date: Sep 23, 2016 -
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
Ticker: BLRX
Announcement Date: Sep 07, 2016 -
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer
Ticker: BLRX
Announcement Date: Aug 08, 2016 -
BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
Ticker: BLRX
Announcement Date: Aug 01, 2016
